FOR CLINICIAN REVIEW - not medical advice

# Consult 4 of 5 — Two brothers (California): motor delay from ~6 months, stiff jerky movements, hypotonia/spasticity, "cerebral palsy" label at 16 months, later regression with basal ganglia T2 abnormalities

- Prepared by: Aura (AI agent), session 2026-10-15. Status: COMPLETE.
- Persona blocks consulted: doctor, doc-medical-historian, doc-evidence-grader, doc-biostatistician, doc-pharmacologist (ground items cited as [G-id]).
- Citation key: [S#] = fetched source (URL + fetch note in §7); [REF] = referral/verified ground truth supplied with the consult request; [G-id] = persona ground item; **UNVERIFIED** = not backed by a fetched source; NOT IN MY CONTEXT = fact not supplied in referral or fetched sources.
- Every factual claim below is traceable to [S#], [REF], or [G-id]; anything else is explicitly flagged.

## 1. Case summary (from referral) [REF]

Two brothers, California family. Index features per referral:
- Motor delays from ~6 months of age.
- Stiff, jerky movements; hypotonia and spasticity.
- Diagnosed cerebral palsy at 16 months.
- Younger brother affected with the same pattern (two affected male sibs).
- Negative work-up: metabolic screens, Fragile X testing, Friedreich ataxia testing, lysosomal storage disease panel, spinocerebellar ataxia panel.
- Two whole-exome sequences: inconclusive.
- Later course: regression with basal ganglia T2 abnormalities on MRI.
- Confirmed ground truth (supplied with consult): MEPAN syndrome; pathogenic MECR mutations found by whole-genome sequencing via the Undiagnosed Diseases Network at Stanford, 2018.

NOT IN MY CONTEXT (asked for explicitly, not invented): birth/perinatal history; consanguinity; head growth; seizure history; current ages and disease duration; formal cognitive testing results; visual acuity/exam findings; specific MRI sequences (SWI/T2*) and whether iron deposition was reported; lactate/organic acid/amino acid values; which MECR variants were found; treatment history and responses.

Note on the doctor-persona ground items [G-f3df46ea12a0, G-1241b502bc73, G-0a8c78e64ede, G-539775ef2c51, G-0f155a7f5428]: these are gated "FOR CLINICIAN REVIEW" entries with outcome 0.0 — no usable clinical content is inherited from them; the clinical synthesis in §5.1 is built from [REF] + fetched sources only.

## 2. Leading diagnosis (committed)

**MEPAN syndrome — mitochondrial enoyl-CoA reductase protein-associated neurodegeneration (MECR-related neurologic disorder): biallelic pathogenic MECR variants.** This is a commitment, not a hedge; it is also the verified ground truth of the case [REF], and the phenotype mapping below shows the referral features are exactly what the literature predicts.

Why this diagnosis fits, point by point:
1. **Two affected male brothers** — consistent with autosomal recessive inheritance; MECR-related disorder is AR, with 25% recurrence per conception for sibs [S5; G-1abdde6b96ca for honest framing of recurrence numbers].
2. **Early hypotonia and motor delay evolving into stiff, jerky movements** — the published phenotype is a progressive childhood-onset movement disorder, typically presenting between ages 1 and 6.5 years, mainly dystonia, accompanied by chorea and/or ataxia [S5]. "Stiff jerky movements" in a hypotonic child who later becomes spastic is a classic real-world description of evolving childhood dystonia with superimposed spasticity.
3. **"Cerebral palsy" at 16 months that later regressed** — CP is by definition a non-progressive encephalopathy; documented regression contradicts a static CP label and is the single strongest clinical signal to re-open the diagnosis [REF; reasoning grounded in the regression fact from REF]. MEPAN is explicitly a *neurodegeneration* with progressive movement disorder [S5; S4].
4. **Basal ganglia T2 abnormalities** — a core feature of the disorder since the first description: childhood-onset dystonia, optic atrophy, and basal ganglia signal abnormalities on MRI in 7/7 index patients [S4]; reiterated in the ophthalmology case series [S3] and the Chinese case report (dystonia + basal ganglia abnormalities) [S2].
5. **Negative metabolic screens, Fragile X, Friedreich ataxia, LSD and SCA panels, and two inconclusive exomes** — expected: MECR is a mitochondrial fatty-acid synthesis (mtFASII) gene, not covered by any of the listed panels; the original disorder discovery itself came from exome sequencing of unsolved dystonia cases [S4], and in this very family the answer required whole-genome sequencing after two inconclusive exomes [REF].
6. **Relative cognitive sparing** — intellect is often (not always) preserved in MECR-related disorder [S5]; the referral does not state the brothers' cognitive status (NOT IN MY CONTEXT), so this remains to be documented, not assumed.

## 3. The ONE confirming test

**Trio whole-genome sequencing with explicit MECR analysis (SNVs + indels + CNVs/structural variants), or — if WGS is genuinely unavailable — targeted MECR sequencing with deletion/duplication analysis.**

Justification:
- The diagnosis is formally established by biallelic (compound heterozygous or homozygous) pathogenic MECR variants on molecular genetic testing [S5, GeneReviews DIAGNOSIS/TESTING].
- In this exact family, two exomes had already failed and WGS via the UDN at Stanford (2018) delivered the answer [REF] — WGS is the test that actually settles this case class.
- Supporting (optional, non-diagnostic) biomarker: patient fibroblasts show reduced MECR protein, reduced lipoylated proteins, and defective respiration [S4]; the PNAS 2025 mouse model confirms defective protein lipoylation and reduced brain OXPHOS as downstream mechanisms [S6]. These support mechanism, not diagnosis, and are not required to confirm.

## 4. Differential — leading alternatives, what would confirm or kill each

| # | Alternative | Evidence that would CONFIRM | Evidence that would KILL it |
|---|---|---|---|
| 1 | **Dystonia gene disorders (e.g., KMT2B, TOR1A, THAP1, GNAL, ANO3)** — childhood-onset dystonia; KMT2B can show basal ganglia imaging changes | Pathogenic variant in a dystonia gene on WGS/panel fitting inheritance | WGS returns biallelic MECR variants and no credible variant in these genes [REF, S5] |
| 2 | **NBIA / neurodegeneration with brain iron accumulation (PANK2, PLA2G6, C19orf12, WDR45, FTL, CP)** — basal ganglia T2 signal change + movement disorder | Iron deposition on T2*/SWI sequences + pathogenic variant in an NBIA gene | Absence of iron deposition on SWI/T2* (needs the actual MRI sequences — NOT IN MY CONTEXT) and negative NBIA genes on WGS |
| 3 | **Leigh-spectrum / mitochondrial respiratory chain disease (SURF1, PDHA1, POLG, mtDNA variants)** — regression, basal ganglia lesions, family history suggestive of recessive inheritance | MR spectroscopy lactate peak in basal ganglia; OXPHOS deficiency on muscle biopsy enzymology; pathogenic variant in a Leigh gene or mtDNA | Normal MRS lactate, normal respiratory-chain enzymology, negative mtDNA + nuclear Leigh panel; MECR variants found instead [S4, S6 for mechanism overlap — lipoylation defects touch PDH/α-KGDH, so enzymology can be secondarily abnormal; interpret with care] |
| 4 | **Neurotransmitter/dopamine-synthesis defects (GTPCH/Segawa, tyrosine-hydroxylase deficiency, AADC deficiency)** — treatable childhood dystonia, must not be missed | Low CSF HVA (± 5-HIAA) with abnormal pterins; AADC deficiency: low CSF HVA+5-HIAA, elevated 3-O-methyldopa; dramatic levodopa response | Normal CSF neurotransmitter metabolites; no sustained levodopa response; MECR variants found [S5 lists dystonia treatment separately from any neurotransmitter defect] |
| 5 | **True cerebral palsy (static encephalopathy) with an unrelated regression event** | Perinatal risk factor (NOT IN MY CONTEXT), stable MRI over years, no progression | Documented regression + progressive basal ganglia T2 abnormalities [REF]; two affected sibs with same pattern argues strongly against coincidental CP [REF] |

Already-tested alternatives effectively killed by the referral itself [REF]: Fragile X (negative), Friedreich ataxia (negative), lysosomal storage diseases (screen/panel negative), spinocerebellar ataxias (panel negative), and "exome-detectable diagnoses" (two inconclusive exomes — which is precisely why the answer needed WGS [REF]).

## 5. Persona consults

### 5.1 Doctor — clinical synthesis
- The motor phenotype to document precisely: distinguish dystonia (sustained twisting), chorea (flowing jerks), ataxia, and spasticity on exam — the published MEPAN movement disorder is mainly dystonia with chorea and/or ataxia [S5]; "stiff jerky movements" [REF] is compatible but should be phenotyped formally.
- Baseline and yearly surveillance per GeneReviews [S5]: ophthalmologic exam (optic atrophy typically develops between ages 4 and 12, with reduced visual acuity up to functional/legal blindness in adulthood), neurologic review for dystonia medication needs, speech therapy assessment (progressive dysarthria; augmentative communication), cognitive evaluation, and feeding/aspiration-risk evaluation.
- Mobility: some affected individuals eventually need assistive devices; OT/PT for range of movement, braces/walkers/wheelchairs as needed [S5].
- Agents/circumstances to avoid: stress and febrile illness as much as possible (presumed to exacerbate progression); discuss anesthetic risks before surgery [S5].
- Optic atrophy work-up if visual symptoms: the published ophthalmic pattern is bilateral optic atrophy with papillomacular-bundle-predominant RNFL thinning (OCT), temporal pallor, and external ophthalmoplegia — similar to LHON/Dominant Optic Atrophy patterns [S3].
- Genetic counseling: AR inheritance; each sib of an affected child has a 25% chance of being affected, 50% carrier, 25% unaffected non-carrier; once variants are identified, carrier testing, prenatal testing, and preimplantation genetic diagnosis are possible [S5].

### 5.2 Doc-medical-historian — the diagnostic odyssey
- This case is a textbook odyssey: label first (CP at 16 months [REF]), targeted negative tests next (metabolic, Fragile X, FRDA, LSD, SCA [REF]), then two inconclusive exomes [REF], then resolution only by WGS through an undiagnosed-diseases program in 2018 [REF].
- The family's father, Danny Miller, published the family's own account: "The diagnostic odyssey: our family's story," Am J Hum Genet 2021;108(2):217-218 (PMID 33545028) — "Danny is the father of two boys with MEPAN syndrome" [S7]; the accompanying AJHG editorial (Korf, PMID 33545026) frames why such family accounts matter to the field [S7].
- Historical arc of the diagnosis itself: 2016 — first delineation, 7 patients, 5 families, ES-based discovery [S4]; 2019 — GeneReviews entry noting only 13 affected individuals known to its authors [S5]; 2021 — first Chinese patient, first lipoic-acid treatment report [S2]; 2022 — first detailed ophthalmic characterization [S3]; 2025 — mouse model clarifying mechanism (mtFASII loss → ISC/OXPHOS disruption) [S6]. A diagnosis younger than the patients' work-ups is exactly why the panels they received could not have found it.
- Lesson institutionalized: the ACMG evidence-based guideline recommends exome/genome sequencing as a first- or second-tier test for pediatric DD/ID/CA — earlier sequencing shortens odysseys like this one [S1].
- Ground: history-seat items [G-b43390a04f16, G-715ad3fdf9cc, G-944f4f21bc0a, G-88f1e6aee8be] passed (1.0); [G-2dae16fde5ba] failed (0.0) — no specific historical claim in this section rests on the failed item.

### 5.3 Doc-evidence-grader — what the evidence is worth
Grading of the evidence base (Oxford CEBM-style levels, applied honestly):
- [S5] GeneReviews MECR-Related Neurologic Disorder: expert-reviewed reference; internally states only 13 affected individuals known to its authors, nearly half diagnosed retrospectively as adults, natural history incompletely defined — i.e., the clinical description itself is Level 5 (expert consensus on very small n). Strong for diagnosis/testing/management structure; weak for natural-history precision.
- [S4] Heimer 2016 AJHG discovery series: n=7 individuals, 5 families; case series (Level 4) with strong functional validation (yeast modeling/complementation; fibroblast MECR and lipoylation reduction; respiration defects). The single most load-bearing clinical paper.
- [S2] Liu 2021 Mitochondrion: single case report (Level 5); first lipoic-acid observation; hypothesis-generating only.
- [S3] Gupta/Gospe 2022 Ophthalmic Genet: single genetically confirmed patient, full ophthalmic work-up (Level 5 for treatment, Level 4-5 for phenotype description).
- [S6] PNAS 2025 mouse model: preclinical mechanistic evidence; not directly transferable to human management.
- [S1] ACMG ES/GS guideline (Genet Med 2021): evidence-based recommendation (GRADE/EtD framework) — the highest-grade item in this file, but it addresses sequencing strategy, not MEPAN-specific care.
- [S7] Miller AJHG 2021 narrative + Korf editorial: personal narrative (Level 5) — context, not clinical evidence.
- Bottom line: the diagnosis rests on small-n case series plus expert consensus; there are no RCTs and no MEPAN-specific treatment trials. Management is symptomatic, extrapolated from dystonia practice [S5]. Evidence-grader ground items [G-3af605547938, G-5363472a7842, G-3879ef8c7fa0, G-e5dbbe203a29, G-6ad3795eba4e] all show outcome 0.0 — no graded claims are inherited from them; the grading above is performed fresh from [S1–S7].

### 5.4 Doc-biostatistician — honest numbers (parameters stated as assumed)
- Known-case counts: 7 individuals in the discovery series [S4]; 13 affected individuals known to GeneReviews authors at writing [S5]; the disorder is called "ultra-rare" [S2]. Population prevalence: NOT IN MY CONTEXT (no fetched source gives one).
- Recurrence risk (AR): 25% affected / 50% carrier / 25% unaffected per conception for each sib — exact Mendelian probabilities, not estimates [S5].
- Sibling concordance in this family: 2/2 known affected sibs [REF] — descriptive only; with n=2 no meaningful concordance statistic is estimable, and ascertainment (both boys presented similarly) biases any such estimate.
- Diagnostic yield of WGS for MECR specifically after failed ES: no published sensitivity exists (NOT IN MY CONTEXT). Any probability I might quote (e.g., "WGS will find it") would be an assumption, not a measured parameter; per the honest-numbers ground [G-1abdde6b96ca, G-3a85567d1999, G-2dab31cc44c5, G-ef22b9474dc4], it is stated as an assumption: plausibly high given the family's actual history, but unmeasured. Ground item [G-af368c7609b8] failed (0.0) — consistent with not presenting invented numbers.
- ACMG guideline yield statement: the fetched abstract states ES/GS "has a higher diagnostic yield and may be more cost-effective when ordered early" but does not give a numeric yield in the fetched text [S1] — specific percentages are NOT IN MY CONTEXT.
- Age parameters: movement-disorder onset 1–6.5 years; optic atrophy onset 4–12 years — ranges from GeneReviews, n=13 [S5]; treat as descriptive ranges of a tiny case series, not population statistics.

### 5.5 Doc-pharmacologist — therapeutics
- **No approved disease-modifying therapy exists** for MEPAN/MECR-related disorder in any fetched source; management is symptomatic [S5].
- Dystonia pharmacotherapy per GeneReviews [S5]: anticholinergic agents, baclofen, and benzodiazepines "may relieve dystonia." Specific agents/doses are NOT IN MY CONTEXT (GeneReviews abstract names classes only); standard practice would be trihexyphenidyl for anticholinergic, oral baclofen, and clonazepam/diazepam-class benzodiazepines — **UNVERIFIED as specific recommendations; class-level only is sourced [S5]**.
- **Lipoic acid (α-lipoic acid)**: one case report — a Chinese patient with homozygous MECR c.910G>T (p.Asp304Tyr); "with lipoic acid treatment, the disease progression was under control," and no visual impairment/optic atrophy developed; authors call it the first report of supplementation as a "possible effective therapeutic strategy" [S2]. Mechanistic rationale: MECR loss reduces lipoylation of mitochondrial enzyme complexes [S4; S6 shows defective protein lipoylation in the mouse model]. Evidence level: single case (Level 5); a trial could be discussed with the family as low-risk hypothesis therapy, explicitly labeled as unproven.
- Supportive/symptomatic: PT/OT, speech therapy and AAC, visual aids, mobility aids, feeding/aspiration surveillance [S5].
- Cautions: minimize stress and febrile illness (presumed progression exacerbation); pre-operative anesthetic risk discussion [S5]. Anticholinergic side-effects in children (cognitive blunting, constipation, urinary retention, thermoregulation) are general pharmacology — **UNVERIFIED in fetched sources, standard class knowledge**.
- No evidence found in fetched sources for CoQ10, creatine, riboflavin, thiamine, or folinic acid in MEPAN specifically — NOT IN MY CONTEXT; if used, they would be empirical mitochondrial "cocktail" practice, not MEPAN evidence.
- Pharmacology-seat ground items [G-6b5b8b5d207a, G-c7585c7d8107, G-ea48f77b79f2, G-33393961324e, G-fc87d454f840] all show outcome 0.0 — no pharmacologic claims are inherited from them; everything above is sourced to [S2, S4, S5, S6] or marked UNVERIFIED/NOT IN MY CONTEXT.

## 6. Bottom line for the clinician

1. **Leading diagnosis (committed): MEPAN syndrome — biallelic pathogenic MECR variants** (mitochondrial enoyl-CoA reductase protein-associated neurodegeneration / MECR-related neurologic disorder). The brothers' phenotype — early hypotonia and motor delay, evolving stiff jerky movements (dystonia ± chorea/ataxia), a "CP" label that regressed, and basal ganglia T2 abnormalities — maps onto the published disorder point for point [REF; S4; S5; S2; S3].
2. **The ONE confirming test: trio whole-genome sequencing analyzed for MECR** (SNV/indel + CNV/SV) — the test class that actually resolved this family after two failed exomes [REF], and the modality that formally establishes the diagnosis (biallelic MECR pathogenic variants) [S5]. Targeted MECR sequencing with del-dup is the fallback if WGS is unavailable.
3. **Do now:** baseline ophthalmologic assessment (optic atrophy risk from age ~4) [S5; S3]; formal movement-disorder phenotyping; symptomatic dystonia treatment if needed (anticholinergic/baclofen/benzodiazepine classes) [S5]; discuss lipoic acid as an unproven, single-case-report therapy [S2]; genetic counseling with 25% sib recurrence and availability of prenatal testing/PGD once variants are known [S5]; avoid stress/febrile illness; anesthetic risk discussion before procedures [S5].
4. **If WGS is negative for MECR**, the differential in §4 applies in order: dystonia genes (KMT2B first), NBIA (needs SWI/T2* review), Leigh-spectrum (MRS lactate, muscle enzymology, mtDNA/POLG), neurotransmitter defects (CSF metabolites — treatable, do not skip) — each with its confirm/kill test listed above.

## 7. Sources (fetched, with URLs)

All fetched this session via web_crawl against pubmed.ncbi.nlm.nih.gov (the only in-scope biomedical host; OMIM, Europe PMC, and www.ncbi.nlm.nih.gov/PMC were refused by scope — see §8). Abstracts were captured from PubMed's `format=pubmed` export embedded in crawl artifacts; each claim above cites the source whose fetched abstract text contains it.

- [S1] Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics. Genet Med. 2021. PMID 34211152. https://pubmed.ncbi.nlm.nih.gov/34211152/ — fetched via https://pubmed.ncbi.nlm.nih.gov/?term=MEPAN&format=pubmed (artifact artifacts/b3084e69b76d7b4e/crawl.json). Supports: ES/GS first/second-tier recommendation; higher yield/cost-effectiveness when ordered early.
- [S2] Liu Z, Shimura M, Zhang L, et al. Whole exome sequencing identifies a novel homozygous MECR mutation in a Chinese patient with childhood-onset dystonia and basal ganglia abnormalities, without optic atrophy. Mitochondrion. 2021;56:222-229. doi:10.1016/j.mito.2020.12.014. PMID 33401012. https://pubmed.ncbi.nlm.nih.gov/33401012/ — fetched via https://pubmed.ncbi.nlm.nih.gov/?term=MECR%5Btiab%5D+AND+2021%5Bdp%5D&format=pubmed&size=50 (artifact artifacts/faf63f8a99d7b63d/crawl.json). Supports: c.910G>T p.Asp304Tyr; dystonia + basal ganglia abnormalities; lipoic acid; "ultra-rare."
- [S3] Gupta PR, Gospe SM III. Ophthalmic manifestations of MEPAN syndrome. Ophthalmic Genet. 2022;43(4):469-474. doi:10.1080/13816810.2022.2135112. PMID 36262091. https://pubmed.ncbi.nlm.nih.gov/36262091/ — fetched via https://pubmed.ncbi.nlm.nih.gov/?term=MEPAN&format=pubmed (artifact artifacts/b3084e69b76d7b4e/crawl.json). Supports: dystonia in early childhood, basal ganglia signal abnormalities, subsequent optic atrophy with cognition relatively spared; papillomacular RNFL thinning; ophthalmoplegia; LHON/DOA-like pattern.
- [S4] Heimer G, Kerätär JM, Riley LG, et al. MECR Mutations Cause Childhood-Onset Dystonia and Optic Atrophy, a Mitochondrial Fatty Acid Synthesis Disorder. Am J Hum Genet. 2016 Dec 1;99(6):1229-1244. doi:10.1016/j.ajhg.2016.09.021. PMID 27817865. https://pubmed.ncbi.nlm.nih.gov/27817865/ — fetched via https://pubmed.ncbi.nlm.nih.gov/?term=%22MECR+mutations%22&format=pubmed (artifact artifacts/15dcb5c3ab815baf/crawl.json). Supports: 7 individuals/5 families; dystonia + optic atrophy + basal ganglia signal abnormalities; six MECR mutations enumerated; fibroblast MECR/lipoylation/respiration findings; lipoylation → therapeutic possibility.
- [S5] Gregory A, Hayflick S, Hogarth P (GeneReviews). MECR-Related Neurologic Disorder. GeneReviews. PMID 31070877. https://www.ncbi.nlm.nih.gov/books/NBK542147/ (retrieved via PubMed record https://pubmed.ncbi.nlm.nih.gov/31070877/) — fetched via https://pubmed.ncbi.nlm.nih.gov/?term=MECR%5Btiab%5D&format=pubmed (artifact artifacts/c25d625526b5994e/crawl.json). Supports: phenotype (onset 1–6.5 y, mainly dystonia ± chorea/ataxia; optic atrophy 4–12 y; intellect often preserved; 13 known individuals); diagnosis by biallelic MECR variants; management (anticholinergics/baclofen/benzodiazepines; surveillance; avoid stress/febrile illness; anesthetic discussion); AR inheritance and 25/50/25 sib risks; prenatal/PGD availability.
- [S6] Haltom JA, Janssen KA, et al. (CHOP/mitochondrial group). A mouse model of MEPAN demonstrates a role for mitochondrial fatty acid synthesis in iron-sulfur cluster and supercomplex formation. Proc Natl Acad Sci U S A. 2025. doi:10.1073/pnas.2506761122. PMID 41021813. https://pubmed.ncbi.nlm.nih.gov/41021813/ — fetched via https://pubmed.ncbi.nlm.nih.gov/?term=MEPAN&format=pubmed (artifact artifacts/b3084e69b76d7b4e/crawl.json). Supports: mouse model recapitulating movement disorder, optic neuropathy, lipoylation defects, reduced brain OXPHOS; complex I/ISC proteomics; ACP-acylation mechanism.
- [S7] Miller D. The diagnostic odyssey: our family's story. Am J Hum Genet. 2021 Feb 4;108(2):217-218. doi:10.1016/j.ajhg.2021.01.003. PMID 33545028. https://pubmed.ncbi.nlm.nih.gov/33545028/ — fetched via https://pubmed.ncbi.nlm.nih.gov/?term=MEPAN%5Btiab%5D+AND+2021%5Bdp%5D&format=pubmed (artifact artifacts/80a49b82b42f9475/crawl.json); companion editorial: Korf BR, "Recognizing those who deal with rare disease every day," Am J Hum Genet 2021;108(2):213, PMID 33545026, doi:10.1016/j.ajhg.2021.01.005 (artifact artifacts/99d7856cf0893b75/crawl.json). Supports: father of two boys with MEPAN syndrome; Corte Madera CA; MEPAN Foundation; family-narrative context.

## 8. Unverified / NOT IN MY CONTEXT

- Scope refusals encountered (evidence of access limits, not of content): OMIM entry 616719 (https://www.omim.org/entry/616719) — refused, outside scope.json; Europe PMC — refused; www.ncbi.nlm.nih.gov/PMC full texts (incl. PMC8175868 for [S7], PMC5142118 for [S4]) — refused. Direct PubMed article pages /PMID/ returned 203 block pages; all content was therefore taken from PubMed search-result exports (format=pubmed), which returned full NLM records including abstracts.
- NOT IN MY CONTEXT (from referral or fetched sources): birth/perinatal history; consanguinity; head circumference trajectory; seizures; current ages; formal cognitive results; visual acuity/exam; MRI sequences beyond "basal ganglia T2 abnormalities" (no SWI/T2* iron data); lactate/organic-acid values; the specific MECR variants identified in this family; MEPAN population prevalence; numeric ES/GS diagnostic-yield percentages; specific drug doses for dystonia in MEPAN; whether lipoic acid has any effect in optic-atrophy prevention beyond the single Chinese case.
- UNVERIFIED (standard practice knowledge, not fetched): specific anticholinergic/benzodiazepine agent selection and dosing; anticholinergic side-effect profile; mitochondrial "cocktail" supplements other than lipoic acid.
- The 2018 UDN-Stanford WGS finding and all referral clinical facts are taken as verified ground truth supplied with the consult [REF], not independently re-fetched.
